Rhoda Alani, MD
Professor
Boston University Chobanian & Avedisian School of Medicine
Dermatology

MD, University of Michigan at Ann Arbor
BS, Stony Brook University



Rhoda M. Alani, MD is Professor of Dermatology at Chobanian and Avedisian School of Medicine and Boston Medical Center, and previously served as the Herbert Mescon Professor and Chair of Dermatology, from 2010-2024. She received her MD degree with Honors and Distinction in Research from the University of Michigan and completed her internship in internal medicine at Yale-New Haven Hospital and a residency in dermatology at Harvard Medical School. From 1999-2009 Dr. Alani was the Director of the Laboratory of Cutaneous Oncology and Director of the Melanoma and Pigmented Lesion Clinics in Dermatology at Johns Hopkins. Dr. Alani’s research focus is in understanding the molecular basis of melanoma development and progression with the aim of translating her laboratory findings to better prevention, detection, diagnosis, and treatment of melanoma. Dr. Alani is a member of Phi Beta Kappa and Alpha Omega Alpha Honor Societies, the American Academy of Dermatology, the Society for Investigative Dermatology, the American Association for Cancer Research and was elected to the American Society for Clinical Investigation in 2005. She is the author of numerous scientific publications and is the owner of several US patents related to melanoma biomarkers, novel melanoma therapies, and imaging systems for improved melanoma detection

Professor
Boston University Chobanian & Avedisian School of Medicine
Pathology & Laboratory Medicine


Member
Boston University
BU-BMC Cancer Center


Member
Boston University
Genome Science Institute


Graduate Faculty (Primary Mentor of Grad Students)
Boston University Chobanian & Avedisian School of Medicine, Graduate Medical Sciences




Leveraged Finance Fights Melanoma – MRA Pilot Award: The CoREST Repressor Complex as a Mediator of RNA Splicing and Tumor Growth
06/01/2023 - 05/31/2025 (PI)
Melanoma Research Alliance


Targeting Epigenetic Modifiers of Phenotype Switching in Targeted Therapy-Resistant Melanoma
09/30/2021 - 09/29/2024 (PI)
Department of Defense/Army Medical Research Acquisition Activity


Targeting Lipids for Melanoma Detection and Prevention
07/01/2021 - 06/30/2023 (Key Person / Mentor)
PI: Marianne Collard, PhD
Melanoma Research Alliance


Epigenetic Regulation of Resistance to Targeted Therapies in Melanoma
06/01/2019 - 05/31/2022 (PI)
Melanoma Research Alliance


Targeting Transcriptional Co-repressor CoREST Complex in Melanoma
06/01/2018 - 08/31/2019 (PI)
Hackensack University Medical Center


Developing Novel Epigenetic Topical Therapy for Psoriasis
07/22/2017 - 07/22/2019 (Key Person / Mentor)
PI: Jean McGee, MD, PhD
Women's Dermatologic Society


p300 Mediates Melanoma Cell Growth and Survival Through the Transcriptional Regulation of MITF
01/01/2017 - 12/31/2017 (Key Person / Mentor)
PI: Edward Kim, MD, PhD
American Skin Association


Center for Innovation in Point of Care Technologies for the Future of Cancer Care
07/01/2012 - 06/30/2017 (Co-Investigator of Sub-Project / SP)
PI: Catherine M. Klapperich, PhD
NIH/National Institute of Biomedical Imaging & Bioengineering
5U54EB015403-04

PESO: Engineered Platforms to Investigate Molecular Determinants of Tumor Metastasis to Targeted Niche Sites
09/01/2012 - 08/31/2016 (Co-Investigator)
PI: Joyce Y Wong, PhD
National Science Foundation
DMR-1235316

Melanoma Assays Based on NRP-2
05/01/2010 - 09/30/2015 (PI)
Laboratory Corporation of America


Showing 10 of 12 results. Show All Results


Title


Yr Title Project-Sub Proj Pubs

Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.

iCite Analysis       Copy PMIDs To Clipboard

  1. Waddell A, Grbic N, Leibowitz K, Wyant WA, Choudhury S, Park K, Collard M, Cole PA, Alani RM. p300 KAT regulates SOX10 stability and function in human melanoma. bioRxiv. 2024 Feb 23.View Related Profiles. PMID: 38469149; PMCID: PMC10926666; DOI: 10.1101/2024.02.20.581224;
     
  2. Wu M, Hanly A, Gibson F, Fisher R, Rogers S, Park K, Zuger A, Kuang K, Kalin JH, Nocco S, Cole M, Xiao A, Agus F, Labadorf A, Beck S, Collard M, Cole PA, Alani RM. The CoREST repressor complex mediates phenotype switching and therapy resistance in melanoma. J Clin Invest. 2024 Feb 01; 134(6).View Related Profiles. PMID: 38300709; PMCID: PMC10940100; DOI: 10.1172/JCI171063;
     
  3. Kida M, Fatima I, Rozhkova E, Otero-Viñas M, Wu M, Kalin JH, Cole PA, Falanga V, Alani RM, Sharov AA. Inhibition of the CoREST Repressor Complex Promotes Wound Re-Epithelialization through the Regulation of Keratinocyte Migration. J Invest Dermatol. 2024 Feb; 144(2):378-386.e2.View Related Profiles. PMID: 37633457; PMCID: PMC10790709; DOI: 10.1016/j.jid.2023.07.022;
     
  4. Amara SV, Grbic N, Melson G, Brem CE, Almier N, Bhawan J, Alani RM, Collard M. Assessment of lipid and pigment content in suspicious melanocytic lesions to improve melanoma detection. Melanoma Res. 2023 Aug 01; 33(4):283-292.View Related Profiles. PMID: 37276030
     
  5. Gibson F, Hanly A, Fisher R, Wyant WA, Wu M, Collard M, Alani RM. Epigenetics and cutaneous neoplasms: from mechanism to therapy. Epigenomics. 2023 Feb; 15(3):167-187.View Related Profiles. PMID: 37020393
     
  6. Gibson F, Hanly A, Grbic N, Grunberg N, Wu M, Collard M, Alani RM. Epigenetic Dysregulation in Autoimmune and Inflammatory Skin Diseases. Clin Rev Allergy Immunol. 2022 Dec; 63(3):447-471.View Related Profiles. PMID: 36346551
     
  7. Hanly A, Gibson F, Nocco S, Rogers S, Wu M, Alani RM. Drugging the Epigenome: Overcoming Resistance to Targeted and Immunotherapies in Melanoma. JID Innov. 2022 Mar; 2(2):100090. PMID: 35199090; PMCID: PMC8844701; DOI: 10.1016/j.xjidi.2021.100090;
     
  8. Lee HJ, Chen Z, Collard M, Chen F, Chen JG, Wu M, Alani RM, Cheng JX. Multimodal Metabolic Imaging Reveals Pigment Reduction and Lipid Accumulation in Metastatic Melanoma. BME Front. 2021; 2021:9860123.View Related Profiles. PMID: 37849907; PMCID: PMC10521760; DOI: 10.34133/2021/9860123;
     
  9. Kam S, Collard M, Lam J, Alani RM. Gut Microbiome Perturbations in Patients with Hidradenitis Suppurativa: A Case Series. J Invest Dermatol. 2021 01; 141(1):225-228.e2.View Related Profiles. PMID: 32422215
     
  10. Anastas JN, Zee BM, Kalin JH, Kim M, Guo R, Alexandrescu S, Blanco MA, Giera S, Gillespie SM, Das J, Wu M, Nocco S, Bonal DM, Nguyen QD, Suva ML, Bernstein BE, Alani R, Golub TR, Cole PA, Filbin MG, Shi Y. Re-programing Chromatin with a Bifunctional LSD1/HDAC Inhibitor Induces Therapeutic Differentiation in DIPG. Cancer Cell. 2019 11 11; 36(5):528-544.e10. PMID: 31631026
     
Showing 10 of 100 results. Show More

This graph shows the total number of publications by year, by first, middle/unknown, or last author.

Bar chart showing 100 publications over 34 distinct years, with a maximum of 10 publications in 2009

YearPublications
19841
19872
19891
19912
19921
19932
19961
19973
19983
19991
20013
20021
20033
20044
20053
20062
20078
20085
200910
20104
20116
20125
20134
20144
20152
20163
20172
20183
20192
20201
20212
20221
20233
20242

2010 MD Anderson Cancer Center: Inaugural Graduate Student Professor of the Year Lecturer
2009 Johns Hopkins University School of Medicine: Stewart Scholar Award in Cancer Research
2008 Johns Hopkins University School of Medicine: Dermatology Residents Leadership and Teaching Recognition Award
2006 Harvard Medical School: Outstanding Alumna
2003 American Skin Association: Scholar Award for Melanoma Research
2001 Stewart Scholar Award in Cancer Research
Contact for Mentoring:

609 Albany St (J Bldg)
Boston MA 02118
Google Map


Alani's Networks
Click the "See All" links for more information and interactive visualizations
Concepts
_
Media Mentions
_
Co-Authors
_
Similar People
_
Same Department